Af­ter Kite Phar­ma stuns an­a­lysts with news of a death in lead CAR-T study, safe­ty ques­tions sour launch fore­cast

There may nev­er have been a right way for Kite Phar­ma to an­nounce that a pa­tient in one of its CAR-T stud­ies died from cere­bral ede­ma — but wait­ing more than a week and then bring­ing it up on the quar­ter­ly call with an­a­lysts def­i­nite­ly wasn’t the way to go. That route seems to have on­ly bright­ened the glar­ing spot­light that im­me­di­ate­ly swiveled over to com­pa­ny ex­ecs as they tried to ex­plain, and down­play, the death.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.